BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15882432)

  • 1. Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype.
    Rao V; Dhar N; Shakila H; Singh R; Khera A; Jain R; Naseema M; Paramasivan CN; Narayanan PR; Ramanathan VD; Tyagi AK
    Scand J Immunol; 2005 May; 61(5):410-7. PubMed ID: 15882432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette-Guérin.
    Rao V; Dhar N; Tyagi AK
    Scand J Immunol; 2003 Oct; 58(4):449-61. PubMed ID: 14507310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis.
    Dey B; Jain R; Gupta UD; Katoch VM; Ramanathan VD; Tyagi AK
    PLoS One; 2011; 6(8):e23360. PubMed ID: 21858087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
    Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
    J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.
    Dai FY; Wang JF; Gong XL; Bao L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
    Tang C; Yamada H; Shibata K; Maeda N; Yoshida S; Wajjwalku W; Ohara N; Yamada T; Kinoshita T; Yoshikai Y
    J Infect Dis; 2008 May; 197(9):1263-74. PubMed ID: 18422438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection.
    Mollenkopf HJ; Kursar M; Kaufmann SH
    J Infect Dis; 2004 Aug; 190(3):588-97. PubMed ID: 15243936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.
    Xu Y; Yang E; Wang J; Li R; Li G; Liu G; Song N; Huang Q; Kong C; Wang H
    Immunology; 2014 Oct; 143(2):277-86. PubMed ID: 24773322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis.
    Coler RN; Campos-Neto A; Ovendale P; Day FH; Fling SP; Zhu L; Serbina N; Flynn JL; Reed SG; Alderson MR
    J Immunol; 2001 May; 166(10):6227-35. PubMed ID: 11342645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aerosol immunization by alginate coated mycobacterium (BCG/MIP) particles provide enhanced immune response and protective efficacy than aerosol of plain mycobacterium against M.tb. H37Rv infection in mice.
    Nagpal PS; Kesarwani A; Sahu P; Upadhyay P
    BMC Infect Dis; 2019 Jul; 19(1):568. PubMed ID: 31262260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis.
    Hwang SA; Kruzel ML; Actor JK
    Int Immunopharmacol; 2005 Mar; 5(3):591-9. PubMed ID: 15683854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterologous Boost Following
    Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
    Front Immunol; 2018; 9():2439. PubMed ID: 30425711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.
    Freches D; Romano M; Korf H; Renauld JC; Van Snick J; Uyttenhove C; Huygen K
    Clin Vaccine Immunol; 2011 Jan; 18(1):95-104. PubMed ID: 21084465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Vaccine Efficacy of the Complete Form of PPE39 Protein from Mycobacterium tuberculosis Beijing/K Strain in Mice.
    Kim A; Hur YG; Gu S; Cho SN
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis.
    Freidag BL; Melton GB; Collins F; Klinman DM; Cheever A; Stobie L; Suen W; Seder RA
    Infect Immun; 2000 May; 68(5):2948-53. PubMed ID: 10768993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.